Skip to content
Screener

Veracyte VCYT Testing revenue — Laboratory supplies and reagents expense

Similar metrics at other companies

Natera, Inc. logo
NTRATesting and laboratory materials from suppliers
$30.92M
Natera, Inc. logo
NTRATesting and laboratory materials from suppliers
$30.92M
Labcorp Holdings logo
LHBiopharma Laboratory Services — Supplies Expense
$121.5M+9.4%
Insight Molecular Diagnostics Inc. logo
IMDXLaboratory Services — Revenue
$32K-98.5%
Aclaris Therapeutics logo
ACRSLaboratory Research Revenue — Revenue
$356K-19.5%
Fulgent Genetics, Inc. logo
FLGTLaboratory Services — Revenue
$71.05M-3.3%

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$3.71B+97.6%
Enterprise value$3.48B+104%
P/E42.2×-29.1×
P/S6.9×+2.9×

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0.0×
Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept vcyt:CostOfRevenueLaboratorySuppliesAndReagentsExpense.

The source filing: Veracyte’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 8:07 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001384101-26-000031
Line itemThree Months Ended March 31, 20262025
Total revenue139,071114,473
Cost of revenue:
Cost of testing revenue:
Laboratory supplies and reagents expense12,31413,067
Sample collection expense3,2882,825
Compensation expense9,8045,611
Other cost of testing revenue (1)4,9373,385
Allocation of facilities and IT expenses2,9633,372

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Veracyte's testing revenue — laboratory supplies and reagents expense?
Veracyte (VCYT) reported testing revenue — laboratory supplies and reagents expense of $12.31M in Q1 2026.
How has Veracyte's testing revenue — laboratory supplies and reagents expense changed year-over-year?
Veracyte's testing revenue — laboratory supplies and reagents expense decreased by 5.8% year-over-year, from $13.07M to $12.31M.
What is the long-term trend for Veracyte's testing revenue — laboratory supplies and reagents expense?
Over 3 years (2022 to 2025), Veracyte's testing revenue — laboratory supplies and reagents expense has grown at a 20.2% compound annual growth rate (CAGR), from $32.99M to $57.29M.
What does testing revenue — laboratory supplies and reagents expense mean?
This captures the variable costs associated with the physical materials, chemical reagents, and consumables required to perform diagnostic tests. It is a key component of the cost of goods sold for laboratory-based service providers.

Ask your AI about Veracyte's testing revenue — laboratory supplies and reagents expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude